Search results
Results from the WOW.Com Content Network
Durvalumab, [11] sold under the brand name Imfinzi, is an anti-cancer medication used for treatment of various types of cancer. [9] It was developed by Medimmune / AstraZeneca . [ 12 ] It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 ( PD-L1 ).
Avelumab (Bavencio) is a fully human IgG1 antibody developed by Merck Serono and Pfizer. Avelumab is FDA approved for the treatment of metastatic merkel-cell carcinoma. It failed phase III clinical trials for gastric cancer. [32] Durvalumab (Imfinzi) is a fully human IgG1 antibody developed by AstraZeneca.
Glyconutrients – types of sugar extracted from plants; they are mostly marketed in a product with the brand name "Ambrotose" by Mannatech, Inc. According to the Memorial Sloan Kettering Cancer Center, these products have been "promoted aggressively to cancer patients" on the basis that they can help cellular health and boost the immune system ...
Imfinzi is a human monoclonal antibody, which works to block a tumour's ability to evade and dampen the immune system, while also boosting the body's anti-cancer immune response, offering an ...
Pembrolizumab (brand name Keytruda) is another PD-1 inhibitor that was approved by the FDA in 2014 and was the second checkpoint inhibitor approved in the United States. [17] Keytruda is approved to treat melanoma and lung cancer and is produced by Merck .
The approval from the U.S. Food and Drug Administration came after a late stage trial showed that Imfinzi along with chemotherapy drugs carboplatin and paclitaxel, then followed by Imfinzi by ...
This is a list of 5α-reductase inhibitors (5α-RIs), drugs which inhibit one or more isoforms of the enzyme 5α-reductase.This enzyme is responsible for the conversion of the androgen hormone testosterone into the more potent dihydrotestosterone (DHT) and is essential for the production of neurosteroids like allopregnanolone, tetrahydrodeoxycorticosterone (THDOC), and 3α-androstanediol from ...
It will be sold under the brand name Journavx. The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.